concept

MYELIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MYELIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1193Connections

17Hypotheses

0Analyses

50Outgoing

50Incoming

7Experiments

0Debates

Summary

MYELIN is a concept in neurodegeneration research. Key relationships include: activates, associated with, inhibits. Associated with ALS, Aging, Als. Connected to 472 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	MYELIN
Key Genes/Proteins	ACAT1, ACETYL-COA, ACHE, ACTB, AGING, AKT
Related Diseases	aging, Aging, Als, ALS, Alzheimer
Related Pathways	Akt

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Myelin Repair Therapies

therapeutic · 1244 words

→

Pathway Diagram

graph TD
    MYELIN["MYELIN"]
    MYELIN -->|"regulates"| Aging["Aging"]
    MYELIN -->|"causes"| ALS["ALS"]
    MYELIN -->|"causes"| Neuropathy["Neuropathy"]
    MYELIN -->|"causes"| Autoimmune["Autoimmune"]
    MYELIN -->|"activates"| Parkinson["Parkinson"]
    MYELIN -->|"activates"| Dementia["Dementia"]
    MYELIN -->|"activates"| Alzheimer["Alzheimer"]
    MYELIN -->|"expressed in"| Tumor["Tumor"]
    oligodendrocytes["oligodendrocytes"] -->|"produces"| MYELIN
    WAM["WAM"] -->|"inhibits"| MYELIN
    Oligodendrocyte["Oligodendrocyte"] -->|"regulates"| MYELIN
    aging["aging"] -->|"causes"| MYELIN
    AQUAPORIN_4["AQUAPORIN-4"] -.biomarker for.-> MYELIN
    PMP22["PMP22"] -->|"causes"| MYELIN
    COMPLEMENT["COMPLEMENT"] -->|"activates"| MYELIN
    AQP4["AQP4"] -->|"causes"| MYELIN
    ASTROCYTES["ASTROCYTES"] -->|"causes"| MYELIN

Outgoing (743)

Target	Relation	Type	Str
MICROGLIA	activates	gene	1.00
Als	activates	disease	1.00
Inflammation	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
INFLAMMATION	activates	gene	1.00
ASTROCYTE	activates	gene	1.00
Als	associated_with	disease	0.95
Alzheimer	activates	disease	0.95
Multiple Sclerosis	therapeutic_target	disease	0.95
OLIGODENDROCYTE	activates	gene	0.90
NEURODEGENERATIVE DISEASES	activates	gene	0.90
MICROGLIA	associated_with	gene	0.90
Multiple Sclerosis	associated_with	disease	0.85
Inflammation	associated_with	disease	0.85
Neuroinflammation	activates	disease	0.85
Tumor	activates	disease	0.85
Multiple Sclerosis	activates	disease	0.85
MSR1	upregulates	gene	0.80
Alzheimer'S Disease	associated_with	disease	0.80
MOG	activates	gene	0.80
MBP	activates	gene	0.80
ASTROCYTES	activates	gene	0.80
ALZHEIMER'S DISEASE	activates	gene	0.80
CYTOKINES	activates	gene	0.80
ALZHEIMER	activates	gene	0.80
Apoptosis	activates	pathway	0.80
Oxidative Stress	activates	pathway	0.80
Autoimmune	causes	disease	0.75
Neurodegeneration	biomarker_for	disease	0.75
OLIGODENDROCYTE	associated_with	concept	0.75
Aging	causes	disease	0.75
NEUROINFLAMMATION	associated_with	concept	0.75
Multiple Sclerosis	biomarker_for	disease	0.75
Neuropathy	causes	disease	0.75
Neuroinflammation	inhibits	disease	0.75
Multiple Sclerosis	causes	disease	0.75
Alzheimer	therapeutic_target	disease	0.75
Inflammation	interacts_with	disease	0.75
Als	causes	disease	0.75
Multiple Sclerosis	regulates	disease	0.75
Neurodegeneration	therapeutic_target	disease	0.75
Parkinson	activates	disease	0.75
Autoimmune	activates	disease	0.75
Als	regulates	disease	0.75
Aging	associated_with	disease	0.75
PHAGOCYTOSIS	regulates	gene	0.70
Differentiation	associated_with	pathway	0.70
Phagocytosis	regulates	pathway	0.70
Nf-Κb	activates	pathway	0.70
NEURODEGENERATION	associated_with	gene	0.70

Incoming (450)

Source	Relation	Type	Str
NEURODEGENERATION	activates	gene	1.00
Oligodendrocyte	associated_with	cell_type	0.95
Oligodendrocytes	associated_with	cell_type	0.95
oligodendrocytes	produces	cell_type	0.90
Aging	causes	process	0.85
OXIDATIVE STRESS	activates	gene	0.80
APOPTOSIS	activates	gene	0.80
TNF	activates	gene	0.80
TREM2	activates	gene	0.80
OLIGODENDROCYTE	associated_with	gene	0.80
WAM	inhibits	cell_type	0.72
AGING	associated_with	gene	0.70
Oligodendrocyte	regulates	entity	0.70
GENES	activates	gene	0.70
PARKINSON'S DISEASE	activates	gene	0.70
NEUROINFLAMMATION	activates	gene	0.70
Oligodendrocyte	activates	entity	0.70
ROS	activates	gene	0.70
STAT3	activates	gene	0.70
MICROGLIA	activates	gene	0.70
TAU	activates	gene	0.70
DISEASE-ASSOCIATED MICROGLIA	activates	gene	0.70
COMPLEMENT	activates	gene	0.70
LRRK2	co_discussed	gene	0.65
NLRP3	co_discussed	gene	0.65
OLIG2	co_discussed	gene	0.65
ABCA1	co_discussed	gene	0.65
CX3CR1	co_discussed	gene	0.65
CLU	co_discussed	gene	0.65
APP	associated_with	gene	0.65
BACE1	associated_with	gene	0.65
CYP46A1	associated_with	gene	0.65
mitochondria	co_discussed	concept	0.65
AXON	associated_with	gene	0.65
AMYLOID	associated_with	gene	0.65
MOG	associated_with	gene	0.65
aging	causes	phenotype	0.64
MICROGLIA ACTIVATION	activates	gene	0.60
AXON	expressed_in	gene	0.60
GSK3B	activates	gene	0.60
MTOR	activates	gene	0.60
NEURON	associated_with	gene	0.60
NEURODEGENERATIVE DISEASES	activates	gene	0.60
SQSTM1	activates	gene	0.60
TAUOPATHY	activates	gene	0.60
LDLR	associated_with	gene	0.60
ASTROCYTE	activates	gene	0.60
GENETIC MODIFIERS	inhibits	gene	0.60
PHAGOCYTOSIS	inhibits	gene	0.60
MICROGLIA	inhibits	gene	0.60

Targeting Hypotheses (17)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Selective Acid Sphingomyelinase Modulation Therapy	0.920	neurodegeneration	Lipid raft composition changes in synapt
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protectio	0.844	neurodegeneration	Lipid raft composition changes in synapt
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct	0.732	neurodegeneration	How do sphingomyelin/ceramide ratios spe
Senescence-Associated Myelin Lipid Remodeling	0.732	neurodegeneration	Senolytic therapy for age-related neurod

Selective Neutral Sphingomyelinase-2 Inhibition Therapy	0.731	neurodegeneration	Lipid raft composition changes in synapt
LXRβ-Selective Agonism as a Precision Therapeutic for APOE4-	0.721	neurodegeneration	What specific molecular mechanisms link
Sphingomyelin Synthase Activators for Raft Remodeling	0.692	neurodegeneration	Lipid raft composition changes in synapt
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution	0.680	neurodegeneration	Neuroinflammation resolution mechanisms
ELF2-Mediated OPC Epigenetic Drift Drives Region-Dependent M	0.650	Alzheimer disease	Allen Mouse Brain Aging Atlas: cross-age
Oligodendrocyte Remyelination Enhancement	0.644	neurodegeneration	Gene expression changes in aging mouse b
Myelin Sulfatide Restoration	0.623	neurodegeneration	Gene expression changes in aging mouse b
BMP4 Pathway Inhibition for Oligodendrocyte Myelination Supp	0.620	neurodegeneration	Cell type vulnerability in Alzheimer's D
Myelin Breakdown-Amyloid Interaction Amplifies Cortical Agin	0.600	Alzheimer disease	Allen Mouse Brain Aging Atlas: cross-age
Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therap	0.599	neurodegeneration	Which cell types show the most significa
MOG-IgG induces spinal cord demyelination through Fcγ recept	0.560	neuroinflammation	What are the specific pathophysiological
Oligodendrocyte Lineage Vulnerability: Early Myelination Dis	0.530	neurodegeneration	Cell type vulnerability debate in Alzhei

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (7)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Proposed experiment from debate on Senolytics targeting p16/p21+ senes	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Proposed experiment from debate on Microglia activate astrocytes via I	falsification	Neuroinflammation	0.400	0.50	cell_line	proposed	$80,000
Iron Dyshomeostasis in MSA Pathogenesis Experiment	validation	Neurodegeneration	0.400	0.50	human	proposed	$2,280,000
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Validation: Membrane-Nucleation in iPSC Neurons	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000
s:** - ALOX15 overexpression in healthy astrocytes should be protectiv	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Role and regulatory mechanism of GPR37 in neurological diseases. [PMID:40822851]	Liu S, Bai T, Liu X, Zhao W, Li X, Sui Y	Front Cell Neurosci	2025	1
Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson's di [PMID:39913287]	Ma Q, Tian JL, Lou Y, Guo R, Ma XR, Wu J	Cell Rep	2025	1
Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotyp [PMID:38816399]	Gao Z, Guo X, Sun Z, Wu S, Wang Q, Huang	Schizophrenia (Heidelb)	2024	1
Inflammation and Infection in Pain and the Role of GPR37. [PMID:36430912]	Zhang Q, Bang S, Chandra S, Ji RR	Int J Mol Sci	2022	1
Osteocalcin attenuates oligodendrocyte differentiation and myelination via GPR37 [PMID:34678058]	Qian Z, Li H, Yang H, Yang Q, Lu Z, Wang	Sci Adv	2021	1
GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. [PMID:30010619]	Bang S, Xie YK, Zhang ZJ, Wang Z, Xu ZZ,	J Clin Invest	2018	1
Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: [PMID:21098459]	Mallat Z, Lambeau G, Tedgui A	Circulation	2010	1
Phospholipase A2 regulation of bovine endometrial (BEND) cell prostaglandin prod [PMID:18811942]	Godkin JD, Roberts MP, Elgayyar M, Guan	Reprod Biol Endocrinol	2008	1
Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468]	["Hsu-Heng Lin", "Hui-An Chen", "Shyh-Je	Molecular genetics & genom	2026	0
Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198]	["Aron Park", "Baeki E Kang", "Eun-Ju Ji	Genes & genomics	2026	0
Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenua [PMID:41754105]	Go Y, Joung H, Han SY, Chung J	Nutrients	2026	0
SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immuno [PMID:41795144]	Xu Y, Liu X, Xu B, Li Q, Zhang L, Li C,	CNS neuroscience & therapeutic	2026	0
A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606]	Yu X MD, Lei J MSc, Du X MSc, He Y MSc,	Int J Surg	2026	0
Plasma metabolites may inhibit childhood obesity by regulating ferroptosis throu [PMID:41249848]	Wang JG, Pan XH, Li Y	Int J Obes (Lond)	2026	0
Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198]	Park A, Kang BE, Jin EJ, Kim HJ, Lee CW	Genes Genomics	2026	0
AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160]	Jia J, Gan Y, Li J, Li L, Meng H et al.	Adv Sci (Weinh)	2026	0
Arachidonic acid analog AACOCF3 suppresses cPLA2-negative NSCLC cell proliferati [PMID:41544858]	Wang H, Wen Z, Jia Y, Tong X, Wang W et	Biochem Pharmacol	2026	0
Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468]	Lin HH, Chen HA, Lin SJ, Hsu RH, Lee NC	Mol Genet Genomic Med	2026	0
Modification of the dermal matrix by senescence associated lipids and its functi [PMID:41690117]	["Jelleschitz S", "Kremslehner C", "Nage	Redox biology	2026	0
Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Ant [PMID:41824764]	Liu H, Aili A, Kuang Z, Cao L, Li Z, Sha	Advanced science (Weinheim, Ba	2026	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity